A surprising bright spot at the FDA on regulating unproven stem cells Two recent actions show that the FDA’s biologics branch continues to take action

https://www.statnews.com/2026/09/03/stem-cell-clinics-fda-cber-warning-letters-marketing/ By Paul KnoepflerSept. 3, 2026 Knoepfler is a professor of cell biology and human anatomy at UC Davis School of Medicine.